Deuterium-enriched lenalidomide
The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
1. A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 8 and R 10 -R 13 are independently selected from H and D; and R 9 is D.
2. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.
3. A method for treating chemotherapy-induced nausea and vomiting comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.
4. A compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt form thereof.
5. A compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt form thereof.
6. A pharmaceutical composition of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.
7. A pharmaceutical composition of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.
8. A method of claim 3 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.
9. A method of claim 3 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.
10. A compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt form thereof.
11. A pharmaceutical composition of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.
12. A method of claim 3 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.